Share Twitter LinkedIn Facebook Email John Burke, MD, Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, discusses Gilteritinib In AML Treatment. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com
Molecular Changes and Patient Stratification – Parrish Phimes, MD Acute Myelogenous Leukemia 2 Mins Read
Inequities in AML Outcomes: Comprehensive Discussion by Pramilla Krishnamurthy Acute Myelogenous Leukemia 2 Mins Read